PURPOSE: This analysis examined associations between gender and health-related quality of life (HRQOL) in patients with B-cell chronic lymphocytic leukemia (CLL) as they initiate therapy for CLL outside the clinical trial setting. METHODS: Baseline data were collected as part of Connect® CLL Registry, a prospective observational study initiated in community, academic, and government centers. Patient demographics and clinical characteristics were provided by clinicians. Patients reported HRQOL using the Brief Fatigue Inventory (BFI), EQ-5D, and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Mean scores were analyzed, with statistical significance of differences determined by ANOVA. Multivariate analysis also considered age and line of therapy. RESULTS: Baseline HRQOL data were available for 1,140 patients: 710 (62 %) men and 430 (38 %) women from 161 centers. Patients were predominantly white (89 %) with mean age 69 ± 11 years. Women reported significantly worse global fatigue (P <0.0001), fatigue severity (P <0.0001), and fatigue-related interference (P = 0.0005) versus men (BFI). Pain/discomfort (P = 0.0077), usual activities (P = 0.0015), and anxiety/depression (P = 0.0117) were significantly worse in women than in men (EQ-5D). With women reporting a better social/family score (P = 0.0238) and men reporting a better physical score (P = 0.0002), the mean FACT-G total score did not differ by gender. However, the mean FACT-Leu total score was better among men versus women (P = 0.0223), primarily because the mean leukemia subscale score was significantly better among men (P <0.0001). Multivariate analysis qualitatively confirmed these findings. CONCLUSIONS: Connect® CLL Registry results indicate that significant differences exist in certain HRQOL domains, as women reported greater levels of fatigue and worse functioning in physical domains.
PURPOSE: This analysis examined associations between gender and health-related quality of life (HRQOL) in patients with B-cell chronic lymphocytic leukemia (CLL) as they initiate therapy for CLL outside the clinical trial setting. METHODS: Baseline data were collected as part of Connect® CLL Registry, a prospective observational study initiated in community, academic, and government centers. Patient demographics and clinical characteristics were provided by clinicians. Patients reported HRQOL using the Brief Fatigue Inventory (BFI), EQ-5D, and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Mean scores were analyzed, with statistical significance of differences determined by ANOVA. Multivariate analysis also considered age and line of therapy. RESULTS: Baseline HRQOL data were available for 1,140 patients: 710 (62 %) men and 430 (38 %) women from 161 centers. Patients were predominantly white (89 %) with mean age 69 ± 11 years. Women reported significantly worse global fatigue (P <0.0001), fatigue severity (P <0.0001), and fatigue-related interference (P = 0.0005) versus men (BFI). Pain/discomfort (P = 0.0077), usual activities (P = 0.0015), and anxiety/depression (P = 0.0117) were significantly worse in women than in men (EQ-5D). With women reporting a better social/family score (P = 0.0238) and men reporting a better physical score (P = 0.0002), the mean FACT-G total score did not differ by gender. However, the mean FACT-Leu total score was better among men versus women (P = 0.0223), primarily because the mean leukemia subscale score was significantly better among men (P <0.0001). Multivariate analysis qualitatively confirmed these findings. CONCLUSIONS: Connect® CLL Registry results indicate that significant differences exist in certain HRQOL domains, as women reported greater levels of fatigue and worse functioning in physical domains.
Authors: Lori M Minasian; Ann M O'Mara; Bryce B Reeve; Andrea M Denicoff; Joseph Kelaghan; Julia H Rowland; Edward L Trimble Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Graça M Dores; William F Anderson; Rochelle E Curtis; Ola Landgren; Evgenia Ostroumova; Elizabeth C Bluhm; Charles S Rabkin; Susan S Devesa; Martha S Linet Journal: Br J Haematol Date: 2007-10-17 Impact factor: 6.998
Authors: Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson Journal: Cancer Date: 2018-05-14 Impact factor: 6.860
Authors: Abigail S Robbertz; David M Weiss; Farrukh T Awan; John C Byrd; Kerry A Rogers; Jennifer A Woyach Journal: Support Care Cancer Date: 2019-07-22 Impact factor: 3.603
Authors: Claudia West; Steven M Paul; Laura Dunn; Anand Dhruva; John Merriman; Christine Miaskowski Journal: Oncol Nurs Forum Date: 2015-09 Impact factor: 2.172
Authors: Travis D Westbrook; Eleshia J Morrison; Kami J Maddocks; Farrukh T Awan; Jeffrey A Jones; Jennifer A Woyach; Amy J Johnson; John C Byrd; Barbara L Andersen Journal: Ann Behav Med Date: 2019-08-16
Authors: Victoria Posternak; Laura B Dunn; Anand Dhruva; Steven M Paul; Judith Luce; Judy Mastick; Jon D Levine; Bradley E Aouizerat; Marylin Hammer; Fay Wright; Christine Miaskowski Journal: Pain Date: 2016-04 Impact factor: 7.926
Authors: K M Holtzer-Goor; M R Schaafsma; P Joosten; E F M Posthuma; S Wittebol; P C Huijgens; E J M Mattijssen; G Vreugdenhil; H Visser; W G Peters; Z Erjavec; P W Wijermans; S M G J Daenen; K G van der Hem; M H J van Oers; C A Uyl-de Groot Journal: Qual Life Res Date: 2015-07-24 Impact factor: 4.147